MCID: SCN036
MIFTS: 46

Secondary Progressive Multiple Sclerosis

Categories: Neuronal diseases, Genetic diseases

Aliases & Classifications for Secondary Progressive Multiple Sclerosis

MalaCards integrated aliases for Secondary Progressive Multiple Sclerosis:

Name: Secondary Progressive Multiple Sclerosis 12 52 14
Multiple Sclerosis, Secondary Progressive 69
Multiple Sclerosis, Chronic Progressive 42
Secondary-Progressive Ms 12
Spms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050783
MeSH 42 D020528
SNOMED-CT 64 425500002
UMLS 69 C0751965

Summaries for Secondary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks.

MalaCards based summary : Secondary Progressive Multiple Sclerosis, also known as multiple sclerosis, secondary progressive, is related to scapuloperoneal myopathy, x-linked dominant and childhood choriocarcinoma of the ovary. An important gene associated with Secondary Progressive Multiple Sclerosis is HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Interferon beta-1b and Interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and t cells, and related phenotypes are cellular and hematopoietic system

Related Diseases for Secondary Progressive Multiple Sclerosis

Diseases in the Primary Progressive Multiple Sclerosis family:

Multiple Sclerosis 4 Multiple Sclerosis 3
Multiple Sclerosis 2 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis

Diseases related to Secondary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
id Related Disease Score Top Affiliating Genes
1 scapuloperoneal myopathy, x-linked dominant 11.1
2 childhood choriocarcinoma of the ovary 10.8 ENO2 MMP9
3 meningitis and encephalitis 10.8 ENO2 S100B
4 leucocyte adhesion defect 10.8 MMP9 S100B
5 drug rash with eosinophilia and systemic symptoms 10.8 IL10 MMP9
6 benallegue lacete syndrome 10.7 ENO2 S100B
7 integrative agnosia 10.7 ENO2 MBP
8 myoma 10.7 ENO2 S100B
9 balkan hemorrhagic fever 10.7 CD40LG IL10
10 enteric pattern testicular yolk sac tumor 10.7 ENO2 S100B
11 endotheliitis 10.7 ENO2 MBP
12 endocervical adenocarcinoma 10.7 ENO2 IFNB1
13 variola major 10.7 CD40LG MBP
14 prader-willi syndrome due to paternal deletion of 15q11q13 type 1 10.7 CCR3 CXCR3
15 chronic duodenal ileus 10.7 CD40LG MBP
16 spoan syndrome 10.6 CD40LG IFNB1
17 myelitis 10.6 CXCR3 IL10 MMP9
18 burn scar 10.6 CXCR3 IL10 MMP9
19 hydromyelia 10.6 ENO2 S100B
20 cogan-reese syndrome 10.6 IFNB1 MBP
21 endocervical type cervical mucinous adenocarcinoma 10.6 ENO2 IL10 MMP9
22 dumping syndrome 10.6 CD40LG IL10
23 tricho onychic dysplasia 10.6 IL10 MBP MMP9
24 facial paralysis 10.6 CD40LG IL10
25 sheehan syndrome 10.6 IL10 MMP9 S100B
26 alopecia intellectual disability syndrome 2 10.6 CXCL10 MBP
27 opthalmoplegia myalgia tubular aggregates 10.6 CXCL10 CXCR3
28 crustacean allergy 10.6 CCR5 IL10
29 atypical lichen myxedematosus 10.5 CCR5 CXCR3
30 gestational diabetes 10.5 CD40LG MBP
31 cervical adenomyoma 10.5 ENO2 MBP S100B
32 vulvar keratoacanthoma-like carcinoma 10.5 ENO2 IFNB1 S100B
33 motor neuron disease 10.5 CD40LG ENO2 S100B
34 acute ackee fruit intoxication 10.5 IL10 IL4
35 pulmonary embolism 10.4 CD40LG IL10 MMP9
36 eye accommodation disease 10.4 IL10 IL4
37 pituitary dwarfism with large sella turcica 10.4 ENO2 S100B
38 ovarian mucinous adenofibroma 10.4 CXCL10 IL10 MBP
39 basidiobolomycosis 10.4 IL10 IL4
40 lagophthalmos 10.4 IL10 IL4
41 hypolipoproteinemia 10.4 CD40LG IFNB1 MBP
42 ulnar neuropathy 10.4 ENO2 MMP9
43 erythema multiforme 10.4 CCR5 CXCL10 IL10
44 thelaziasis 10.4 IL10 IL4
45 hemolytic anemia due to triosephosphate isomerase deficiency 10.3 CD40LG CXCL10 CXCR3
46 deafness, autosomal recessive 22 10.3 IL10 IL4
47 rocky mountain spotted fever 10.3 CD40LG CXCL10
48 ovarian surface papilloma 10.3 IL10 MBP
49 ectropion 10.3 CXCR3 IL4 MMP9
50 ulcerative colitis 10.3 ENO2 IL10 MBP S100B

Graphical network of the top 20 diseases related to Secondary Progressive Multiple Sclerosis:



Diseases related to Secondary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Secondary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Secondary Progressive Multiple Sclerosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 RORC CCR2 CCR3 CCR5 CD40LG CXCL10
2 hematopoietic system MP:0005397 10.15 IFNB1 IL10 IL4 MBP MMP9 RORC
3 homeostasis/metabolism MP:0005376 10.13 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
4 immune system MP:0005387 10.03 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
5 nervous system MP:0003631 9.65 CCR2 CCR5 CD40LG CXCL10 ENO2 IFNB1
6 neoplasm MP:0002006 9.63 CCR2 CCR5 CXCR3 IFNB1 IL10 MMP9
7 respiratory system MP:0005388 9.17 CXCR3 ENO2 IL10 IL4 MMP9 CCR2

Drugs & Therapeutics for Secondary Progressive Multiple Sclerosis

Drugs for Secondary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 192)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
2
Interferon beta-1a Approved, Investigational Phase 4,Phase 2 145258-61-3 6438354
3
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3 624-49-7 5271565 637568
4
Mitoxantrone Approved, Investigational Phase 4,Phase 3 65271-80-9 4212
5
4-Aminopyridine Approved Phase 4,Phase 3 504-24-5 1727
6
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 189261-10-7
7
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
8 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
9 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
10 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
11 Interferon-beta Phase 4,Phase 3,Phase 2
12 interferons Phase 4,Phase 3,Phase 2
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
17 Dermatologic Agents Phase 4,Phase 3,Phase 1,Early Phase 1
18 Topoisomerase Inhibitors Phase 4,Phase 3
19 Fingolimod Hydrochloride Phase 4
20 Potassium Channel Blockers Phase 4,Phase 3
21 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
22 glucocorticoids Phase 4,Phase 3,Phase 1
23 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
26
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
27
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1 83-43-2 6741
28
Prednisolone Approved, Vet_approved Phase 3,Phase 1 50-24-8 5755
29
Morphine Approved, Investigational Phase 3 57-27-2 5288826
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1,Early Phase 1 59-30-3 6037
31
Epigallocatechin gallate Investigational Phase 2, Phase 3 989-51-5 65064
32 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Early Phase 1
33 Alkylating Agents Phase 3
34 Antiemetics Phase 3,Phase 2,Phase 1
35 Autonomic Agents Phase 3,Phase 2,Phase 1
36 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
37 Methylprednisolone acetate Phase 3,Phase 1
38 Methylprednisolone Hemisuccinate Phase 3,Phase 1
39 Neuroprotective Agents Phase 3,Phase 2,Phase 1
40 Prednisolone acetate Phase 3,Phase 1
41 Prednisolone hemisuccinate Phase 3,Phase 1
42 Prednisolone phosphate Phase 3,Phase 1
43 Protective Agents Phase 3,Phase 2,Phase 1
44 Antioxidants Phase 2, Phase 3, Phase 1
45 Micronutrients Phase 2, Phase 3,Phase 1
46 Thioctic Acid Phase 2, Phase 3,Phase 1
47 Trace Elements Phase 2, Phase 3,Phase 1
48 Vitamin B Complex Phase 2, Phase 3,Phase 1,Early Phase 1
49 Vitamins Phase 2, Phase 3,Phase 1
50 Vaccines Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 115)

id Name Status NCT ID Phase Drugs
1 Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS Completed NCT00463710 Phase 4 Avonex® monotherapy (6.0 MIU administered i.m. each week)
2 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
3 Open-Label Safety Extension Study of Avonex Completed NCT00915460 Phase 4 Interferon beta-1a (Avonex)
4 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
5 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
6 Long-term Follow-up of Fingolimod Phase II Study Patients Completed NCT02307838 Phase 4
7 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Active, not recruiting NCT02208050 Phase 4 Fampridine;Placebo
8 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients Active, not recruiting NCT03092544 Phase 4 dimethyl fumarate
9 BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Not yet recruiting NCT03269175 Phase 4
10 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4 Prednisone;Placebo
11 Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Terminated NCT01701856 Phase 4 Interferon beta-1b
12 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
13 Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Completed NCT00241254 Phase 3 Cyclophosphamide (drug);Methylprednisolone (drug)
14 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
15 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Completed NCT01917019 Phase 3 Placebo;BIIB041 (fampridine)
16 Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity Completed NCT01538225 Phase 3 Sativex®;Placebo
17 Sunphenon in Progressive Forms of Multiple Sclerosis Completed NCT00799890 Phase 2, Phase 3 Sunphenon EGCG;Placebo
18 Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis Completed NCT00134563 Phase 3 Teriflunomide;Placebo (for teriflunomide)
19 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Recruiting NCT01433497 Phase 2, Phase 3 masitinib;placebo
20 Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Recruiting NCT02688985 Phase 3 Ocrelizumab
21 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) Active, not recruiting NCT01665144 Phase 3 BAF312;Placebo
22 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3 MD1003 100mg capsule
23 A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Not yet recruiting NCT02057159 Phase 2, Phase 3
24 A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Terminated NCT01416181 Phase 3 natalizumab;Placebo
25 Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3 MBP8298
26 Study Evaluating Mitoxantrone in Multiple Sclerosis Terminated NCT00146159 Phase 3 Mitoxantrone
27 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
28 A Study for Patients With Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
29 Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) Withdrawn NCT00313976 Phase 3 Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
30 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
31 The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis Unknown status NCT01144117 Phase 2 Erythropoietin
32 Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Unknown status NCT02273635 Phase 1, Phase 2 Andrographolides;placebo
33 Combination Therapy of Betaseron-Prograf in Multiple Sclerosis Unknown status NCT00298662 Phase 2 Interferon beta-1b and Tacrolimus
34 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
35 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Completed NCT00257855 Phase 2 Lamotrigine
36 Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis Completed NCT02228213 Phase 2 Saline
37 Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis Completed NCT00647348 Phase 2 Simvastatin;Placebo
38 Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01450488 Phase 2 masitinib;masitinib
39 Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis Completed NCT01684761 Phase 2
40 Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis Completed NCT01056471 Phase 1, Phase 2
41 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2 Natalizumab
42 Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Completed NCT00342134 Phase 2
43 Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis Completed NCT01191996 Phase 1, Phase 2
44 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Completed NCT01982942 Phase 2 ibudilast;Placebo
45 Treatment of Multiple Sclerosis Using Over the Counter Inosine Completed NCT00067327 Phase 2 Inosine
46 Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) Completed NCT00086671 Phase 2 ABT-874/Human monoclonal antibody against IL-12;Placebo
47 A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) Completed NCT00436826 Phase 2 Cladribine;Placebo;Interferon-beta (IFN-beta)
48 Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis Completed NCT00587691 Phase 1, Phase 2
49 Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses Completed NCT00228163 Phase 2 teriflunomide (HMR1726)
50 Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis Completed NCT00071838 Phase 2 Daclizumab

Search NIH Clinical Center for Secondary Progressive Multiple Sclerosis

Cochrane evidence based reviews: multiple sclerosis, chronic progressive

Genetic Tests for Secondary Progressive Multiple Sclerosis

Anatomical Context for Secondary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Secondary Progressive Multiple Sclerosis:

39
Brain, B Cells, T Cells, Cortex, Thyroid, Myeloid

Publications for Secondary Progressive Multiple Sclerosis

Articles related to Secondary Progressive Multiple Sclerosis:

(show top 50) (show all 107)
id Title Authors Year
1
Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controlled trial. ( 28770099 )
2018
2
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. ( 28600189 )
2017
3
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. ( 28045953 )
2017
4
Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis. ( 28801580 )
2017
5
Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. ( 28572730 )
2017
6
Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. ( 28145395 )
2017
7
Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. ( 28905255 )
2017
8
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. ( 28429241 )
2017
9
Corpus callosum atrophy as a marker of clinically meaningful cognitive decline in secondary progressive multiple sclerosis. Impact on employment status. ( 28601572 )
2017
10
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. ( 28396953 )
2017
11
Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. ( 28838904 )
2017
12
Markers of oxidative/nitrative damage of plasma proteins correlated with EDSS and BDI scores in patients with secondary progressive multiple sclerosis. ( 28521618 )
2017
13
Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? ( 27753181 )
2017
14
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. ( 28594298 )
2017
15
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals. ( 27685028 )
2016
16
iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles. ( 27965675 )
2016
17
Correction to: The role of MRI in the evaluation of secondary progressive multiple sclerosis. ( 27032440 )
2016
18
White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis. ( 26733423 )
2016
19
Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells. ( 27570566 )
2016
20
Secondary Progressive Multiple Sclerosis: Definition and Measurement. ( 27166830 )
2016
21
Expression of DNA methylation genes in secondary progressive multiple sclerosis. ( 26711572 )
2016
22
Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis. ( 27739247 )
2016
23
The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. ( 27507559 )
2016
24
Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis. ( 27620894 )
2016
25
Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient. ( 27430119 )
2016
26
The role of MRI in the evaluation of secondary progressive multiple sclerosis. ( 26692498 )
2016
27
Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis. ( 27339072 )
2016
28
Defining secondary progressive multiple sclerosis. ( 27401521 )
2016
29
Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis - study site experience based on the therapy of 104 patients. ( 27919195 )
2016
30
Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study. ( 27636543 )
2016
31
Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. ( 26943957 )
2016
32
HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS. ( 27917400 )
2016
33
Brain perfusion imaging with voxel-based analysis in secondary progressive multiple sclerosis patients with a moderate to severe stage of disease: a boon for the workforce. ( 27229156 )
2016
34
The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis. ( 27513853 )
2016
35
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. ( 26788129 )
2016
36
Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. ( 27996064 )
2016
37
The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences. ( 27803641 )
2016
38
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. ( 26943959 )
2016
39
Patterns of white matter damage are non-random and associated with cognitive function in secondary progressive multiple sclerosis. ( 27408797 )
2016
40
RORI^t Expression and Lymphoid Neogenesis in the Brain of Patients with Secondary Progressive Multiple Sclerosis. ( 27413074 )
2016
41
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. ( 27003945 )
2016
42
Modeling The Natural History of Secondary-Progressive Multiple Sclerosis: A New Modeling Approach Using Discrete Event Simulation. ( 26533922 )
2015
43
Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis. ( 25856304 )
2015
44
Cortical sources of resting state electroencephalographic rhythms differ in relapsing-remitting and secondary progressive multiple sclerosis. ( 26111485 )
2015
45
Evaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial. ( 26566454 )
2015
46
Brainstem glioblastoma in a patient with secondary progressive multiple sclerosis. ( 25990103 )
2015
47
A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis. ( 25595252 )
2015
48
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis. ( 26589141 )
2015
49
Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36. ( 26533994 )
2015
50
A 10-year follow-up of the European multicenter trial of interferon I^-1b in secondary-progressive multiple sclerosis. ( 26362898 )
2015

Variations for Secondary Progressive Multiple Sclerosis

ClinVar genetic disease variations for Secondary Progressive Multiple Sclerosis:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> C (p.Phe273Leu) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
2 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> G (p.Phe273Val) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
3 HNRNPA1 NM_002136.3(HNRNPA1): c.841T> C (p.Phe281Leu) single nucleotide variant Pathogenic rs483353031 GRCh37 Chromosome 12, 54677685: 54677685

Expression for Secondary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Secondary Progressive Multiple Sclerosis.

Pathways for Secondary Progressive Multiple Sclerosis

Pathways related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CCR2 CCR5 CD40LG CXCL10 IFNB1 IL10
2
Show member pathways
13.47 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
3
Show member pathways
13.18 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
4
Show member pathways
13.03 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
5
Show member pathways
13.02 CCR2 CCR5 CD40LG CXCL10 IFNB1 IL10
6
Show member pathways
12.75 CCR2 CCR3 CCR5 CXCL10 CXCR3
7 12.42 CCR2 CD40LG CXCL10 IL10 IL4
8
Show member pathways
12.3 CCR5 CD40LG IL10 IL4
9
Show member pathways
12.21 CXCL10 IL4 MMP9 RORC
10
Show member pathways
12.13 CCR5 CD40LG IL10 IL4
11
Show member pathways
12 IFNB1 IL10 IL4
12 11.86 CCR3 IL10 IL4
13 11.81 IL10 IL4 MMP9 RORC
14 11.78 CCR2 CCR5 IFNB1 IL10
15 11.63 CCR2 CXCL10 IL4 MBP MMP9
16 11.61 CD40LG IL10 IL4
17 11.61 CXCR3 IL10 IL4 RORC
18 11.54 CD40LG IL10 IL4
19
Show member pathways
11.44 CCR2 CCR3 CCR5 CXCL10 CXCR3
20 11.42 CCR2 CCR3 IL4 MMP9
21 11.23 CCR2 CD40LG MMP9
22 11.15 IFNB1 IL10 IL4
23 11.08 CD40LG CXCL10 IL10 IL4
24 10.71 CCR2 CCR5 CXCL10 IL10 IL4

GO Terms for Secondary Progressive Multiple Sclerosis

Cellular components related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CD40LG CXCL10 ENO2 IFNB1 IL10 IL4
2 external side of plasma membrane GO:0009897 9.02 CCR5 CD40LG CXCL10 CXCR3 IL4

Biological processes related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.83 CCR5 CXCL10 CXCR3 IFNB1
2 immune response GO:0006955 9.8 CCR2 CCR5 CD40LG CXCL10 IL10 IL4
3 cellular response to lipopolysaccharide GO:0071222 9.75 CCR5 CXCL10 IL10
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.73 CCR2 CCR3 CCR5 CXCR3
5 inflammatory response GO:0006954 9.7 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
6 B cell differentiation GO:0030183 9.67 CD40LG IFNB1 IL10 IL4
7 cellular defense response GO:0006968 9.62 CCR2 CCR3 CCR5 IL4
8 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.59 IL10 MMP9
9 defense response to protozoan GO:0042832 9.58 IL10 IL4
10 B cell proliferation GO:0042100 9.58 CD40LG IFNB1 IL10
11 positive regulation of monocyte chemotaxis GO:0090026 9.57 CCR2 CXCL10
12 negative regulation of nitric oxide biosynthetic process GO:0045019 9.56 IL10 IL4
13 dendritic cell chemotaxis GO:0002407 9.55 CCR2 CCR5
14 T cell chemotaxis GO:0010818 9.54 CXCL10 CXCR3
15 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.51 IL10 MBP
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.49 IL10 IL4
17 type 2 immune response GO:0042092 9.48 IL10 IL4
18 regulation of isotype switching GO:0045191 9.46 IL10 IL4
19 chemokine-mediated signaling pathway GO:0070098 9.35 CCR2 CCR3 CCR5 CXCL10 CXCR3
20 chemotaxis GO:0006935 9.1 CCR2 CCR3 CCR5 CXCL10 CXCR3 IL4

Molecular functions related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 CD40LG CXCL10 IFNB1 IL10 IL4
2 C-C chemokine binding GO:0019957 9.26 CCR3 CCR5
3 C-C chemokine receptor activity GO:0016493 9.13 CCR2 CCR3 CCR5
4 chemokine receptor activity GO:0004950 8.92 CCR2 CCR3 CCR5 CXCR3

Sources for Secondary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....